Study of JI-101 in Patients With Advanced Low Grade Endocrine Tumors, Ovarian Cancers or K-RAS Mutant Colon Cancers

NCT01149434 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

19

Enrollment

OTHER

Sponsor class

Stopped Lack of drug efficacy

Conditions

Cancer
Neuroendocrine
Ovarian Cancer
Colon Cancer

Interventions

DRUG: JI-101
DRUG: Everolimus

Sponsor

University of Utah

Collaborators

[object Object]